ATE207747T1 - Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems - Google Patents

Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems

Info

Publication number
ATE207747T1
ATE207747T1 AT94403014T AT94403014T ATE207747T1 AT E207747 T1 ATE207747 T1 AT E207747T1 AT 94403014 T AT94403014 T AT 94403014T AT 94403014 T AT94403014 T AT 94403014T AT E207747 T1 ATE207747 T1 AT E207747T1
Authority
AT
Austria
Prior art keywords
evaluation
vincristin
active ingredients
nervous system
central nervous
Prior art date
Application number
AT94403014T
Other languages
English (en)
Inventor
Francois-Xavier Coude
Jacqueline Fournier
Umberto Guzzi
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE207747T1 publication Critical patent/ATE207747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94403014T 1990-05-22 1991-05-21 Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems ATE207747T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
ATE207747T1 true ATE207747T1 (de) 2001-11-15

Family

ID=9396855

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91401311T ATE132369T1 (de) 1990-05-22 1991-05-21 Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten
AT94403014T ATE207747T1 (de) 1990-05-22 1991-05-21 Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT91401311T ATE132369T1 (de) 1990-05-22 1991-05-21 Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten

Country Status (16)

Country Link
US (3) US5229389A (de)
EP (2) EP0458696B1 (de)
JP (2) JP2618115B2 (de)
KR (1) KR0181330B1 (de)
AT (2) ATE132369T1 (de)
BR (1) BR9105015A (de)
CA (2) CA2042974C (de)
CY (1) CY2283B1 (de)
DE (2) DE69115989T2 (de)
DK (2) DK0458696T3 (de)
FR (1) FR2662355B1 (de)
HU (1) HU208922B (de)
IE (1) IE911707A1 (de)
IL (3) IL112167A (de)
TW (1) TW216771B (de)
ZA (1) ZA913865B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
ES2159362T3 (es) * 1995-10-26 2001-10-01 Sanofi Synthelabo Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
WO1997037228A1 (en) * 1996-03-29 1997-10-09 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
AU1607397A (en) * 1997-02-03 1998-08-25 Sanofi-Synthelabo Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3, 6-tetrahydropyrid-1YL)-2-(6,7-dimethoxynapht-2-YL) ethane for preparing medicines for the treatment of cerebral and neuronal disorders
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
ATE132369T1 (de) 1996-01-15
KR910019617A (ko) 1991-12-19
DE69115989T2 (de) 1996-08-22
CA2365832C (en) 2007-08-07
US5468753A (en) 1995-11-21
EP0655247B1 (de) 2001-10-31
DE69115989D1 (de) 1996-02-15
CA2042974C (en) 2002-09-17
IE911707A1 (en) 1991-12-04
ZA913865B (en) 1992-02-26
HK1001471A1 (en) 1998-06-19
AU7713391A (en) 1991-11-28
BR9105015A (pt) 1993-05-25
DE69132797D1 (de) 2001-12-06
DK0458696T3 (da) 1996-05-20
DK0655247T3 (da) 2002-02-18
JP2618115B2 (ja) 1997-06-11
CY2283B1 (en) 2003-07-04
IL112167A (en) 1996-01-31
IL98175A (en) 1996-01-19
EP0458696B1 (de) 1996-01-03
CA2042974A1 (en) 1991-11-22
DE69132797T2 (de) 2002-05-29
EP0655247A1 (de) 1995-05-31
AU636488B2 (en) 1993-04-29
HU911729D0 (en) 1991-12-30
EP0458696A2 (de) 1991-11-27
IL112167A0 (en) 1995-03-15
US5270320A (en) 1993-12-14
KR0181330B1 (ko) 1999-03-20
IL98175A0 (en) 1992-06-21
FR2662355A1 (fr) 1991-11-29
JP2954029B2 (ja) 1999-09-27
EP0458696A3 (en) 1992-03-18
IE20011078A1 (en) 2002-03-20
JPH09132535A (ja) 1997-05-20
FR2662355B1 (fr) 1994-11-10
HU208922B (en) 1994-02-28
CA2365832A1 (en) 1991-11-23
HUT59824A (en) 1992-07-28
US5229389A (en) 1993-07-20
TW216771B (de) 1993-12-01
JPH04226917A (ja) 1992-08-17

Similar Documents

Publication Publication Date Title
ATE207747T1 (de) Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems
DE69100547D1 (de) Methode und Vorrichtung zum elektrochemischen Bearbeiten der Spritzöffnungen von Brennstoff-Einspritzdüsen.
DE69128362D1 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
AT368656B (de) Optisch auslesbarer scheibenfoermiger aufzeichnungstraeger, verfahren zu dessen herstellung und vorrichtung zur durchfuehrung dieses verfahrens
DE3780691D1 (de) Methode und geraet zur regelung des kraftstoffeinspritzzeitpunkts und der kraftstoffeinspritzmenge.
DE68925727D1 (de) Methode zur Bestimmung der optimalen Arbeitsbedingungen in einem elektrochemischen Detektor und elektrochemischer Detektor, diese Methode benutzend
DE3763289D1 (de) Ultrafiltrations-, hyperfiltrations- oder entmineralisierungselement, verfahren zu seiner herstellung und seine verwendung zur aufbereitung von fluessigen, radioaktiven abfaellen.
DE3871260D1 (de) Partielles abbauprodukt von proteinen, verfahren zu seiner herstellung und seine verwendung.
DE3485319D1 (de) Rekombinante dns, diese rekombinante dns enthaltende bakterien, und verfahren zur herstellung von l-threonin oder l-isoleucin unter verwendung dieser bakterien.
DE58901151D1 (de) Verfahren zur herstellung von katalysatoren und ihre verwendung zur herstellung von isocyanuratgruppen aufweisenden polyisocyanaten.
Rickson et al. Social bases of farmers' responses to land degradation.
DE69012808D1 (de) Vorrichtung zur behandlung von lebenden fischen und fischbrut und deren verwendung.
AT383491B (de) Vorrichtung zum verabreichen von voll- oder sitz- baedern, insbesondere unter verwendung von peloid
DE59000468D1 (de) Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen.
DE3864229D1 (de) Verfahren und vorrichtung zur bestimmung der mittleren feinheit von losen fasern.
DE3852345D1 (de) Methode zur Messung von Impuls-Parametern.
DE3484909D1 (de) Verfahren zur herstellung von biologisch aktiven stoffen.
DE3579782D1 (de) Verfahren zur herstellung von harnstoffgruppen enthaltenden polyisocyanaten.
DE3865794D1 (de) Hydroraffinationskatalysator, ausgehend von hydrogelen, verfahren zur herstellung und verwendung.
DE3865649D1 (de) Apatitfuellmaterial zur fluessigchromatografie und verfahren zu seiner herstellung.
DE58905617D1 (de) Verfahren zur Überwachung und/oder Regelung eines Spritzgiessprozesses.
ATE9343T1 (de) 2,6-diethyl-3,5-dimethyl-2,3-dihydro-4h-pyran, verfahren zu seiner herstellung und seine verwendung zur frueherkennung, lokalisierung und bekaempfung von lasioderma serricorne f.
AT367821B (de) Verfahren zur erhoehung der standfestigkeit von plastischem, tonig-schluffigem gebirge und vorrichtung zur durchfuehrung des verfahrens
DE3773331D1 (de) Optisch aktives propanon-derivat, verfahren zu seiner herstellung und seine verwendung.
ATA77785A (de) Pruefmodell zur verwendung in sterilisiergeraeten, insbesondere beim sterilisieren von biologische stoffe enthaltendem sterilisiergut

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee